Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Journal: 2012/January - British Journal of Pharmacology
ISSN: 1476-5381
Abstract:
Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL(-1) . They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant. http://dx.doi.org/10.1111/bph.2011.163.issue-7.
Relations:
Content
Citations
(147)
References
(218)
Clinical trials
(1)
Drugs
(2)
Chemicals
(1)
Organisms
(3)
Processes
(1)
Similar articles
Articles by the same authors
Discussion board
Br J Pharmacol 163(7): 1344-1364

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects

Click here to view.(458K, pptx)
GW Pharmaceuticals, Salisbury, Wiltshire, UK
Ethan Russo, MD, 20402 81st Avenue SW, Vashon, WA 98070, USA. E-mail: ten.tsacmoc@ossurnahte
GW Pharmaceuticals, Salisbury, Wiltshire, UK
Received 2010 Nov 19; Revised 2010 Dec 29; Accepted 2011 Jan 12.

Abstract

Tetrahydrocannabinol (THC) has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of cannabidiol to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids, including tetrahydrocannabivarin, cannabigerol and cannabichromene, exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. This review will explore another echelon of phytotherapeutic agents, the cannabis terpenoids: limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol and phytol. Terpenoids share a precursor with phytocannabinoids, and are all flavour and fragrance components common to human diets that have been designated Generally Recognized as Safe by the US Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent, and affect animal and even human behaviour when inhaled from ambient air at serum levels in the single digits ng·mL. They display unique therapeutic effects that may contribute meaningfully to the entourage effects of cannabis-based medicinal extracts. Particular focus will be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal and bacterial infections (including methicillin-resistant Staphylococcus aureus). Scientific evidence is presented for non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index. Methods for investigating entourage effects in future experiments will be proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant.

LINKED ARTICLES

This article is part of a themed issue on Cannabinoids in Biology and Medicine. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.163.issue-7

Keywords: cannabinoids, terpenoids, essential oils, THC, CBD, limonene, pinene, linalool, caryophyllene, phytotherapy
Abstract

Acknowledgments

The author offers appreciation to the following individuals, who provided materials and/or consultation: David Potter, Etienne de Meijer, John McPartland, David Watson, Rob Clarke, Indalecio Lozano, Támas Bíró, José Crippa, Roger Pertwee, Colin Stott, Vincenzo Di Marzo, Luciano De Petrocellis, Patrick McGovern, John Riddle and Elisaldo Carlini. Most of all, I would like to thank Raphael Mechoulam for his example, guidance, friendship, a life of good works and for listening to many ‘crazy ideas’.

Acknowledgments

Glossary

Abbreviations

2-AG2-arachidonoylglycerol
5-HT5-hydroxytryptamine (serotonin)
ADantidepressant
AEAarachidonoylethanolamide (anandamide)
AIanti-inflammatory
AMPAα-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate
Ca++calcium ion
CB1/CB2cannabinoid receptor 1 or 2
CBCcannabichromene
CBCAcannabichromenic acid
CBDcannabidiol
CBDAcannabidiolic acid
CBDVcannabidivarin
CBGcannabigerol
CBGAcannabigerolic acid
CBGVcannabigerivarin
CNScentral nervous system
COXcyclo-oxygenase
DAGLdiacylglycerol lipase
ECSendocannabinoid system
EOessential oil
FAAHfatty acid amidohydrolase
FDAUS Food and Drug Administration
FEMAFood and Extract Manufacturers Association
fMRIfunctional magnetic resonance imaging
GABAgamma aminobutyric acid
GPCRG-protein coupled receptor
GPRG-protein coupled receptor
HEKhuman embryonic kidney
IC5050% inhibitory concentration
i.pintraperitoneal
MAGLmonoacylglycerol lipase
MICminimum inhibitory concentration
MSmultiple sclerosis
NGFnerve growth factor
NIDAUS National Institute on Drug Abuse
PGprostaglandin
PTSDpost-traumatic stress disorder
RCTrandomized clinical trial
SPECTsingle photon emission computed tomography
SSADHsuccinic semialdehyde dehydrogenase
Sxsymptoms
T1/2half-life
TCAtricyclic antidepressant
THCtetrahydrocannabinol
THCAtetrahydrocannabinolic acid
THCVtetrahydrocannabivarin
TNF-αtumour necrosis factor-alpha, TRPV, transient receptor potential vanilloid receptor
Glossary

References

Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.